Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

5
Celgene: Fears Are Overplayed

2018-07-10 seekingalpha
The stock is cheap providing the ability for the company to continue reducing the share count at a 10% rate.
GILD JUNO NATCOPHARM 524816 CELG

29
Market Live: Sensex falls 300 pts, metals lose shine; Europe falls 1% amid trade tensions

2018-07-02 moneycontrol
Europe Update: Shares in Europe opened sharply lower as investors question the stability of the German government and wider trade links between the European Union and the US.
BAJAJ-AUTO BHRYY 500325 524816 RELIANCE IDBI TCHQY ICLQY 532977 BHRQY 532755 500470 NATCOPHARM 534816 RIGD 500477 INFRATEL 500570 BHARTIARTL TATAMOTORS RLNIY ASHOKLEY 500116 VOD VOD TATAPOWER 532822 AKLD TECHM 532454 506022 TTST VODPF TATASTEEL TATLY PRAKASH IDEA 500102 TPCL 500400 BALLARPUR AKLS TTM

0
Natco Pharma stock rises 3% post launch of anti-HCV drug in India

2018-07-02 moneycontrol
Natco Pharma share price jumped as much as 3 percent in morning on Monday after the launch of drug that is used for the treatment of Hepatitis C, in India.
NATCOPHARM 524816

0
Natco Pharma Limited - Press Release

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

25
Market Live: Sensex falls 150 pts, Nifty falls below 10,700 amid trade concerns

2018-07-02 moneycontrol
Buzzing: Natco Pharma share price jumped as much as 3 percent in morning after the launch of drug that is used for the treatment of Hepatitis C, in India.
BAJAJ-AUTO 500325 ADANIENT 533096 524816 RELIANCE 539254 TCHQY 532977 512599 532755 500470 NKE NATCOPHARM RIGD 500570 TATAMOTORS RLNIY ADANITRANS ANNRY TECHM 506022 TTST TATASTEEL TATLY PRAKASH ADANIPOWER TTM

8
Portfolio picks: These 5 stocks can be multibaggers in the next 2-3 years

2018-06-20 moneycontrol
Soumen Chatterjee, Director Research, Guiness Securities, expects one more rate hike in the latter half of the year, given the surge in oil prices. “If the monsoon remains normal as predicted by the India Meteorological Department, we will see a dovish stance from the Monetary Policy Committee accompanied by a 25 bps rate hike later in the year.”
ICICIBANK 532540 NATCOPHARM 532174 IBN 524816 TCS HEXAWARE 532129 TTNQY

0
Natco Pharma up 3% on launching generic Posaconazole injection in India

2018-06-11 moneycontrol
Shares of Natco Pharma rose 3.6 percent intraday Monday as company has launched a generic version of Posaconazole Injection, 300 mg/16.7ml, under its brand POSANAT.
NATCOPHARM 524816

0
Natco Pharma Limited - Press Release

2018-06-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

0
How Natco defied the odds to rise up India#39;s pharma ladder

2018-06-06 moneycontrol
For the second year in a row, drugmaker Natco Pharma has rewarded its employees with a one-time special bonus even as peers, both large and small, are tightening their purse strings besieged with pricing pressure in the US coupled with lacklustre growth in domestic formulation market.
AUROPHARMA NATCOPHARM 524804 ARBQY 524816

0
Natco Pharma Limited - Reply to Clarification- Financial results

2018-05-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

0
Natco Pharma Limited - Financial Result Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

0
Natco Pharma Limited - Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

0
Natco Pharma Limited - Outcome of Board Meeting

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
NATCOPHARM 524816

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...